Peripheral blood concentrations of TGFβ1, IGF-1 and bFGF and remodelling of the left ventricle and blood vessels in hypertensive patients

Kardiologia Polska

Volumn 68, Issue 9, 2010, Pages 996-1002

  Kieć Wilk, Beata ^a   Stolarz Skrzypek, Katarzyna ^a   Śliwa, Agnieszka ^a   Zdzienicka, Anna ^a   Kawecka Jaszcz, Kalina ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

bFGF; Essential hypertension; Growth factors; IGF 1; Intima media thickness; Left ventricular hypertrophy; TGF 1

Indexed keywords

ANTIHYPERTENSIVE AGENT; BASIC FIBROBLAST GROWTH FACTOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL PARAMETERS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL;

EID: 77958561257     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Chao W, D'Amore PA. IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev, 2008; 19: 111-120.
2. Chen CH, Poucher SM, Lu J et al. Fibroblast growth factor 2: from laboratory evidence to clinical application. Curr Vasc Pharmacol, 2004; 2: 33-43.
3. Gordon KJ, Blobe GC. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta, 2008; 1782: 197-228.
4. Scaglione R, Argano C, di Chiara T et al. Central obesity and hypertensive renal disease: association between higher levels of BMI, circulating transforming growth factor beta1 and urinary albumin excretion. Blood Press, 2003; 12: 269-276 (Pubitemid 38128473)
5. Kiec-Wilk B, Kawecka-Jaszcz K, Stolarz K et al. Czynniki wzrostu i cytokiny (TGF, bFGF i IGF-1) a przerost miȩśnia lewej komory serca w nadciśnieniu tȩtniczym. Kardiol Pol, 2006; 64: 10 (supl. 6): 586-590.
6. Baker KM, Chernin MI, Schreiber T et al. Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regul Pept, 2004; 120: 5-13.
7. Huang CY, Buchanan DL, Gordon RL Jr et al. Increased insulin- like growth factor-I gene expression precedes left ventricular cardiomyocyte hypertrophy in a rapidly-hypertrophying rat model system. Cell Biochem Funct, 2003; 21: 355-361.
8. Derhaschnig U, Shehata M, Herkner H et al. Increased levels of transforming growth factor-beta1 in essential hypertension. Am J Hypertens, 2002; 15: 207-211.
9. Pellieux C, Foletti A, Peduto G et al. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest, 2001; 108: 1843-1851.
10. Watkins SJ, Jonker L, Arthur HM. A direct interaction between TGFbeta activated kinase 1 and the TGFbeta type II receptor: implications for TGFbeta signalling and cardiac hypertrophy. Cardiovasc Res, 2006; 69: 432-439. (Pubitemid 43098799)
11. Diez J, Laviades C. Insulin-like growth factor I and collagen type III synthesis in patients with essential hypertension and left ventricular hypertrophy. J Hum Hypertens, 1994; 8: S21-S25.
12. Parrinello G, Licata A, Colomba D et al. Left ventricular filling abnormalities and obesity-associated hypertension: relationship with overproduction of circulating transforming growth factor beta1. J Hum Hypertens, 2005; 19: 543-550. (Pubitemid 40946039)
13. Li G, Borger MA, Williams WG, Weisel RD et al. Regional overexpression of insulin-like growth factor-I and transforming growth factor-beta1 in the myocardium of patients with hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg, 2002; 123: 89-95.
14. Li RK, Li G, Mickle DA, Weisel RD et al. Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation, 1997; 96: 874-881.
15. Dabek J, Kułach A, Monastyrska-Cup B et al. Transforming growth factor beta and cardiovascular diseases: the other facet of the 'protective cytokine'. Pharmacol Rep, 2006; 58: 799-805.
16. Ito Y, Nakachi K, Imai K, Hashimoto S et al. Stability of frozen serum levels of insulin-like growth factor-I, insulin-like growth factor-II, insulin-like growth factor binding protein-3, transforming growth factor beta, soluble Fas, and superoxide dismutase activity for the JACC study. J Epidemiol, 2005; 15: S67-S73. (Pubitemid 41403844)
17. Pulford BE, Ishii DN. Uptake of circulating insulin-like growth factors (IGFs) into cerebrospinal fluid appears to be independent of the IGF receptors as well as IGF-binding proteins. Endocrinology, 2001; 142: 213-220.
18. Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. Vasc Health Risk Manag, 2007; 3: 783-795.
19. Zanchetti A, Bond MG, Hennig M et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial; European Lacidipine Study on Atherosclerosis investigators. Circulation, 2002; 106: 2422-2427.
20. Naya M, Tsukamoto T, Morita K et al. Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients. Hypertens Res, 2007; 30: 541-548.
21. Migliore T, Parrella LS, Caputi A et al. Pathogenesis of hypertrophic cardiomyopathy. Impact of growth factors on left ventricular anatomy. Minerva Cardioangiol, 2008; 56: 13-20.
22. Lebrin F, Deckers M, Bertolino P et al. TGF-beta receptor function in the endothelium. Cardiovasc Res, 2005; 65: 599-608.
23. Watanabe T, Itokawa M, Nakagawa Y et al. Increased levels of insulin-like growth factor binding protein-3 in hypertensive patients with carotid atherosclerosis. Am J Hypertens, 2003; 16: 754-760.
24. Colao A, Spiezia S, Di Somma C et al. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. J Endocrinol Invest, 2005; 28: 440-448.
25. Rosenkranz S, Flesch M, Amann K et al. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol, 2002; 283: H1253-H1262.
26. House SL, Bolte C, Zhou M et al. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation, 2003; 108: 3140-3148.
27. Kobayashi N, Nakano S, Mori Y et al. Benidipine inhibits expression of ET-1 and TGF-beta1 in Dahl salt-sensitive hypertensive rats. Hypertens Res, 2001; 24: 241-250.
28. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodelling. Cardiovasc Res, 2004; 63: 423-432.
29. Kuschnir E. The left ventricle and hemodynamic patterns in essential hypertension. Regul Pept, 2005; 128: 221-225.
30. Galderisi M, Vitale G, Lupoli G et al. Inverse association between free insulin-like growth factor-1 and isovolumic relaxation in arterial systemic hypertension. Hypertension, 2001; 38: 840-845.
31. Frossard PM, Pravica V, Perrey C et al. Lack of association between human TGF-beta1 gene variants and primary hypertension. Am J Hypertens, 2000; 13: 944-945.